IL179528A0 - Novel use of peptide compounds for treating amyotrophic lateral sclerosis - Google Patents

Novel use of peptide compounds for treating amyotrophic lateral sclerosis

Info

Publication number
IL179528A0
IL179528A0 IL179528A IL17952806A IL179528A0 IL 179528 A0 IL179528 A0 IL 179528A0 IL 179528 A IL179528 A IL 179528A IL 17952806 A IL17952806 A IL 17952806A IL 179528 A0 IL179528 A0 IL 179528A0
Authority
IL
Israel
Prior art keywords
lateral sclerosis
amyotrophic lateral
peptide compounds
novel use
treating amyotrophic
Prior art date
Application number
IL179528A
Original Assignee
Sanol Arznei Schwarz Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from EP04013636A external-priority patent/EP1604656A1/en
Application filed by Sanol Arznei Schwarz Gmbh filed Critical Sanol Arznei Schwarz Gmbh
Publication of IL179528A0 publication Critical patent/IL179528A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL179528A 2004-06-09 2006-11-23 Novel use of peptide compounds for treating amyotrophic lateral sclerosis IL179528A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57806304P 2004-06-09 2004-06-09
EP04013636A EP1604656A1 (en) 2004-06-09 2004-06-09 Novel use of peptide compounds for treating amyotrophic lateral sclerosis (ALS)
PCT/EP2005/006169 WO2005120476A2 (en) 2004-06-09 2005-06-08 Novel use of peptide compounds for treating amyotrophic lateral sclerosis

Publications (1)

Publication Number Publication Date
IL179528A0 true IL179528A0 (en) 2008-03-20

Family

ID=35219356

Family Applications (1)

Application Number Title Priority Date Filing Date
IL179528A IL179528A0 (en) 2004-06-09 2006-11-23 Novel use of peptide compounds for treating amyotrophic lateral sclerosis

Country Status (2)

Country Link
IL (1) IL179528A0 (en)
NO (1) NO20070129L (en)

Also Published As

Publication number Publication date
NO20070129L (en) 2007-03-06

Similar Documents

Publication Publication Date Title
IL246171B (en) Processes for the preparation of peptide-based compounds
ZA200801253B (en) Novel use of peptide compounds for treating muscle pain
EP1789086A4 (en) Extended treatment of multiple sclerosis
ZA200609021B (en) Novel use of peptide compounds for treating essential tremor and other tremor syndromes
HK1203055A1 (en) Treatment for multiple sclerosis
EP1714960A4 (en) Novel therapeutic agent for amyotrophic lateral sclerosis (als) or disease attributable to als
EP1685259A4 (en) Biomarkers for amyotrophic lateral sclerosis
PL1801108T3 (en) Morpholine compounds for the treatment of inflammations
IL177055A0 (en) Silinae compounds as cysteine protease inhibitors
EP1888056A4 (en) Use of ladostigil for the treatment of multiple sclerosis
ZA200708033B (en) Tetrahydro-pyridoazepin-8-ones and related compounds for the treatment of schizophrenia
SI1855674T1 (en) Composition for inhibition of cathepsin k
IL179337A0 (en) Pharmaceutical compositions for the treatment of pruritus
EP2050467A4 (en) Therapeutic agent for amyotrophic lateral sclerosis
IL177735A0 (en) Combined pharmaceutical composition for the inhibition of the decline of cognitive functions
GB0400802D0 (en) Compounds for the treatment of disease
IL179528A0 (en) Novel use of peptide compounds for treating amyotrophic lateral sclerosis
AU2003260618A8 (en) Treatment of amyotrophic lateral sclerosis using pgc-1 activity-modulating compounds
GB0618403D0 (en) Treatment of amyotrophic lateral sclerosis
ZA200606780B (en) Compounds for the treatment of diseases
HU0500947D0 (en) Composition for treatment of paradontosis
IL179072A0 (en) Novel use of peptide compounds for treating dyskinesia
HUP0500948A2 (en) Composition for treatment of diabeticus paradontosis
EP1874283A4 (en) Use of novel compounds for ibd treatment
GB0317128D0 (en) Use of antitumoral compounds